Peptidic+probiotic (DrugBank: -)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
96 | クローン病 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04305535 (ClinicalTrials.gov) | February 13, 2020 | 5/3/2020 | Impact of an Oligomeric Diet in Intestinal Absorption and Inflammatory Markers in Patients With Crohn Disease | Clinical Trial to Evaluate the Effect of an Oligomeric Oral Nutritional Supplement on the Response in Intestinal Absorption and Inflammation, in Patients With CROHN Disease | Crohn Disease;Absorption; Disorder, Protein; Disorder; Disorder, Fat; Disorder, Carbohydrate;Malnutrition | Dietary Supplement: Peptidic+Probiotic;Dietary Supplement: Peptidic+Placebo;Dietary Supplement: Polymeric+Placebo | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Adventia Pharma, S.L.;Biopolis S.L. | Recruiting | 18 Years | N/A | All | 162 | N/A | Spain |